Upregulating APOAV expression by statins via PPAR-α activated pathway possibly contributes to their triglyceride-lowering effect

Bioscience Hypotheses

Volumn 1, Issue 6, 2008, Pages 292-294

  Bai, Lin ^a   Zhao, Shui ping ^a   Huang, Xian sheng ^a   Zhang, Qian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Apolipoprotein AV; Peroxisome proliferator activated receptor ; Triglyceride

Indexed keywords

APOLIPOPROTEIN A5; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG MECHANISM; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC REGULATION; HUMAN; HYPERTRIGLYCERIDEMIA; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

EID: 57049106796     PISSN: 17562392     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bihy.2008.08.007     Document Type: Article

References (22)

1. Malloy M.J., and Kane J.P. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med 47 (2001) 111-136
2. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
3. van der Vliet H.N., Sammels M.G., Leegwater A.C., Levels J.H., Reitsma P.H., Boers W., et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 276 (2001) 44512-44520
4. Pennacchio L.A., and Rubin E.M. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 23 (2003) 529-534
5. Pennacchio L.A., Olivier M., Hubacek J.A., Krauss R.M., Rubin E.M., and Cohen J.C. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11 (2002) 3031-3038
6. Talmud P.J., Hawe E., Martin S., Olivier M., Miller G.J., Rubin E.M., et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11 (2002) 3039-3046
7. Henneman P., Schaap F.G., Havekes L.M., Rensen P.C., Frants R.R., van Tol A., et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 193 (2007) 129-134
8. Wong K., and Ryan R.O. Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation. Curr Opin Lipidol 18 (2007) 319-324
9. Vu-Dac N., Gervois P., Jakel H., Nowak M., Bauge E., Dehondt H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278 (2003) 17982-17985
10. Prieur X., Coste H., and Rodriguez J.C. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem 278 (2003) 25468-25480
11. Jakel H., Nowak M., Moitrot E., Dehondt H., Hum D.W., Pennacchio L.A., et al. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 279 (2004) 45462-45469
12. Genoux A., Dehondt H., Helleboid-Chapman A., Duhem C., Hum D.W., Martin G., et al. Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORα. Arterioscler Thromb Vasc Biol 25 (2005) 1186-1192
13. Prieur X., Schaap F.G., Coste H., and Rodríguez J.C. Hepatocyte nuclear factor-4-α regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by peroxisome proliferator-activated receptor-γ coactivator-1α, AMP-activated protein kinase, and mitogen-activated protein kinase pathway. Mol Endocrinol 19 (2005) 3107-3125
14. Scharnagl H., and März W. New lipid-lowering agents acting on LDL receptors. Curr Top Med Chem 5 (2005) 233-242
15. Kasim S.E., LeBoeuf R.C., Khilnani S., Tallapaka L., Dayananda D., and Jen K.L. Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. J Lipid Res 33 (1992) 1-7
16. Yokoyama M., Seo T., Park T., Yagyu H., Hu Y., Son N.H., et al. Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle. J Lipid Res 48 (2007) 646-655
17. Roglans N., Sanguino E., Peris C., Alegret M., Vázquez M., Adzet T., et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 302 (2002) 232-239
18. Landrier J.F., Thomas C., Grober J., Duez H., Percevault F., Souidi M., et al. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J Biol Chem 279 (2004) 45512-45518
19. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 107 (2001) 1423-1432
20. Paumelle R., and Staels B. Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins. Circ Res 100 (2007) 1394-1395
21. Davidson M.H. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 111 (2005) 2280-2281
22. Paumelle R., Blanquart C., Briand O., Barbier O., Duhem C., Woerly G., et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98 (2006) 361-369